| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC1106 | PCI-32765 (Ibrutinib) Featured | PCI-32765 (Ibrutinib) is a potent and highly selective Btk inhibitor with IC50 of 0.5 nM. |
|
| DC8078 | PD 153035(AG-1517) Featured | PD 153035(AG-1517) is an ultra-potent inhibitor of epidermal growth factor receptor tyrosine kinase (EGFRK), with an IC50 of 25 pM. |
|
| DC5021 | PD153035 HCl (SU-5271, AG1517) Featured | PD153035 is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM; little effect noted against PGDFR, FGFR, CSF-1, InsR and Src. |
|
| DC7842 | PD158780 Featured | PD158780 is a very potent inhibitor of EGFR with IC50 of 0.08 nM; pan-specific antagonist of ErbB receptor. |
|
| DC10068 | PD166866 Featured | PD-166866 is a selective inhibitor of the FGF-1 receptor tyrosine kinase (FGFR1) with IC50 = 55 nM, and no effect on c-Src, PDGFR-b, EGFR or insulin receptor tyrosine kinases or MEK, PKC, and CDK4. |
|
| DC9258 | PD168393 Featured | PD168393 is potent, cell-permeable, irreversible and selective inhibitor of EGF receptor (EGFR) tyrosine kinase and ErbB2. |
|
| DC2054 | PD-173074 Featured | PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM. |
|
| DC7571 | PD173955 Featured | PD-173955 is a src tyrosine kinase inhibitor. PD173955 inhibited Bcr-Abl-dependent cell growth. |
|
| DC7225 | Pelitinib (EKB-569; WAY-EKB 569) Featured | Pelitinib (EKB-569; WAY-EKB 569) is a potent irreversible EGFR inhibitor with IC50 of 38.5 nM. |
|
| DC4106 | PF573228 Featured | PF 573228 is a inhibitor of FAK with IC50 of 4 nM. |
|
| DC3168 | PF-562271 PHSO3H SALT Featured | PF-00562271 is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK and Pyk2 with IC50 of 1.5 nM and 14 nM, respectively. |
|
| DC7081 | PF-04217903 Featured | PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant). |
|
| DC10631 | PF-06273340 | PF-06273340 is a highly potent, kinases elective, well-tolerated pan-Trk inhibitor with IC50 values of 6, 4, 3 nM for TrkA, TrkB, Trk C, respectively. |
|
| DC11722 | PF-06459988 | PF-06459988 (PF06459988, PF 6459988) is a potent, selective, irreversible EGFR mutants with IC50 of 13, 7, 21 and 90 nM for EGFR L858R-T790M, Del-T790M, L858R, and EGFR Del, respectively. |
|
| DC7924 | PF06463922(Lorlatinib) Featured | PF06463922 is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. |
|
| DC2047 | Crizotinib (PF-2341066) Featured | PF-2341066 (Crizotinib) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nnM, respectivley. |
|
| DC1091 | PF-299804 (Dacomitinib,PF-00299804) Featured | PF299804 is a potent, irreversible pan-ErbB inhibitor against ErbB1, ErbB2 and ErbB4 with IC50 of 6 nM, 45.7 nM and 73.7 nM, respectively. |
|
| DC7941 | PF-431396 Featured | PF-431396 is dual focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2) inhibitor , PF-431396 has a Kd value of 445 nM for BRD4. |
|
| DC8526 | PF4618433 Featured | PF-4618433 shows improved PYK2 potency, reduced p38 activity, and superior overall selectivity relative to the prototype BIRB796. |
|
| DC3169 | PF-562271 Featured | PF-562271 is a potent, ATP-competitive, reversible inhibitor of FAK and Pyk2 with IC50 of 1.5 nM and 14 nM, respectively. |
|
| DC11320 | PF-6274484 | PF-6274484 is an inhibitor of the EGF receptor (EGFR; IC50s = 0.18 and 0.14 nM for wild-type EGFR and inhibitor-resistant EGFRL858R/T790M, respectively). |
|
| DC7230 | PHA-665752 Featured | PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM, >50-fold selectivity for c-Met than RTKs or STKs. |
|
| DC8158 | Pexidartinib(PLX3397) Featured | PLX3397 is a tyrosine kinase inhibitor that potently inhibits the colony stimulating factor 1 (CSF1) receptor kinase, a driving force in the development and growth of PVNS. |
|
| DC7241 | PND-1186 Featured | PND-1186 is a potent FAK inhibitor with IC50 of 1.5 nM. |
|
| DC11914 | Poseltinib Featured | Poseltinib (HM-71224, LY-3337641) is a potent and selective, covalent inhibitor of Btk with IC50 of 1.95 nM. |
|
| DC7704 | Poziotinib Featured | Poziotinib, is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity. |
|
| DC10641 | PRN1371 Featured | PRN1371 is an irreversible covalent FGFR1-4 kinase inhibitor, with IC50s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, 2, 3, 4 and CSF1R, respectively. |
|
| DC7948 | PRT-060318(PRT318) Featured | PRT-060318 is a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. |
|
| DC5197 | Quizartinib (AC220) Featured | Quizartinib (AC220) is a second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM, 10-fold more selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R. Phase 1/2. |
|
| DC1014 | R406 free base Featured | R406 is a potent Syk inhibitor with IC50 of 41 nM and also potently inhibits Flt3. |
|
